FSSAI Cracks Down on Nutraceutical Labelling Violations
The Food Safety and Standards Authority of India (FSSAI) has issued a stern advisory regarding nutraceutical labelling norms. Specifically, the food regulator expressed serious concern over widespread non-compliance by manufacturers of health supplements and botanical extracts. Consequently, authorities have warned of strict penalties, including licence cancellation, against non-compliant food business operators. Many companies continue to omit statutory cautionary notices and disclaimers. Therefore, clinicians must remain vigilant when evaluating consumer supplements that flood clinical discussions.
Regulatory Mandates on Nutraceutical Labelling Norms
Under the 2016 regulations, manufacturers must state permissible ingredient limits and explicitly declare plant parts. Furthermore, the framework strictly prohibits brands from marketing formulations with medicinal claims or promises of disease cures. Clear warning statements remain essential to prevent misuse among vulnerable populations, including children and pregnant women. In addition, botanical ingredients governed under Schedule IV possess potent physiological effects that demand transparent disclosure. Hence, regulators require prominent cautionary statements about known side effects, contraindications, and potential drug-herb interactions.
Clinical Implications for Medical Practitioners
Patients frequently self-prescribe health supplements under the mistaken belief that natural formulations carry zero clinical risks. However, botanical extracts can trigger adverse events or interact dangerously with conventional prescription medications. Because substandard labels obscure active dosages, clinicians face heightened diagnostic complexity during acute presentations. Moreover, physicians must actively query patients about non-prescription supplement intake during routine clinical evaluations. Ultimately, educating patients on unapproved therapeutic claims protects them from delayed conventional care and unexpected toxicity.
Frequently Asked Questions
Q1: Why did FSSAI issue this new advisory on nutraceuticals?
FSSAI issued the advisory because several manufacturers failed to print mandatory warning statements and botanical details on packaging.
Q2: Can nutraceutical manufacturers advertise disease cures under Indian law?
No, statutory regulations strictly prohibit manufacturers from making medicinal claims or advertising curative properties on supplement packaging.
Q3: How do non-compliant nutraceutical labels affect clinical patient care?
Undisclosed ingredients and missing warnings increase the risk of unexpected adverse interactions with conventional pharmaceutical prescriptions.
References
- FSSAI warns against violation of mandatory labelling norms for nutraceuticals,health supplements - ETHealthworld
- FSSAI directs food business operators to comply with labelling norms, warnings for plant-based ingredients - The New Indian Express
- FSSAI warns nutraceutical firms over labelling violations, threatens action for non-compliance - Mint
